Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Radiotherapy plays a central part in curing cancer. For decades, most research on
improving treatment outcomes has focused on modulating radiation-induced biological …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary
disease with a median survival of 2–4 years after diagnosis. A significant number of IPF …

Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis
using animal models, yet few of these compounds have replicated these beneficial effects in …

The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the
treatment of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was …

Extracellular matrix (ECM) is an essential component of skeletal muscle. It provides a
framework structure that holds myofibers and blood capillaries and nerves supplying the …

Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …